---
document_datetime: 2024-12-10 14:38:28
document_pages: 21
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/dovato-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: dovato-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 11.253559
conversion_datetime: 2025-12-28 17:25:29.216091
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Dovato

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                                        | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| WS/2751/G            | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.a.1.z - Change in the manufacturer of AS or of a | 31/10/2024                          | n/a                                         |                                  |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| starting material/reagent/intermediate variation B.I.a.1.f - Change in the starting material/reagent/intermediate Changes to quality control the AS -replacement or batch control/testing takes A.7 - Administrative change manufacturing sites A.4 - Administrative change and/or address of a manufacturer or supplier of the AS, starting intermediate used in the manufacturer of a novel A.4 - Administrative change and/or address of a manufacturer or supplier of the AS, starting intermediate used in the manufacturer of a novel B.I.a.3.a - Change in batch ranges) of AS or intermediate increase compared to the size B.I.a.3.a - Change in batch ranges) of AS or intermediate increase compared to the size B.I.a.1.a - Change in the starting material/reagent/intermediate proposed manufacturer pharmaceutical group as   |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

| WS/2620   | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Update of section 4.6 of the SmPC in order to update information about the use of DTG-containing regimens in pregnancy and at conception based on final results from non-interventional Tsepamo study and the Eswatini Birth Outcomes Surveillance study. In addition, data from other cohort studies and pregnancy registries, including the APR, DOLOMITE- EPPICC (Study 208613) and DOLOMITE-NEAT-ID Network study (Study 208759) both listed as category 3 studies in the RMP; and the US Chart Review (Study 212976) as well as data from literature are included. DOLOMITE-EPPICC (Study 208613) is a non-interventional study to assess 'real-world' maternal and foetal outcomes following DTG use during pregnancy and to describe patterns of DTG utilization; DOLOMITE NEAT ID Network Study (208759) is a non-interventional, multi-site observational study to define the safety and effectiveness of dolutegravir use in HIV positive pregnant women. In addition, the MAH took the opportunity to implement editorial changes to sections 4.4 and 4.5 of the SmPC. The package leaflet is updated accordingly. The RMP version 19.0 (Tivicay), version 23.1 (Triumeq), version 5.0   | 31/10/2024   | SmPC and PL   |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|---------------|

<div style=\"page-break-after: always\"></div>

|                     | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                               |            |            |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0050             | B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)                                                                       | 19/07/2024 |            | SmPC and PL            |                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| N/0049              | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                | 15/07/2024 |            | Labelling and PL       |                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| IA/0048             | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                   | 10/04/2024 | n/a        |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| R/0045              | Renewal of the marketing authorisation.                                                                                                                                                                         | 25/01/2024 | 21/03/2024 | SmPC and PL            | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Dovato in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity. Only changes to the Product information (PI) to bring it in line with the current QRD template version 10.3 and SmPC guidelines are introduced with this renewal procedure. |
| PSUSA/10075 /202301 | Periodic Safety Update EU Single assessment - dolutegravir, dolutegravir / abacavir / lamivudine, dolutegravir / lamivudine                                                                                     | 14/09/2023 | 14/09/2023 | SmPC and PL            | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10075/202301.                                                                                                                                                                                                                                                                                                       |
| IB/0041/G           | This was an application for a group of variations. B.II.e.1.b.1 - Change in immediate packaging of the finished product - Change in type/addition of a new container - Solid, semi-solid and non-sterile liquid | 06/09/2023 | 21/03/2024 | SmPC, Labelling and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                  |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | pharmaceutical forms B.II.e.1.b.1 - Change in immediate packaging of the finished product - Change in type/addition of a new container - Solid, semi-solid and non-sterile liquid pharmaceutical forms                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |            |     |           |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------|
| IB/0042/G | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate | 22/08/2023 | n/a | B.I.b.2.e |

<div style=\"page-break-after: always\"></div>

|             | starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |            |     |    |
|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|----|
| IG/1655/G   | This was an application for a group of variations. B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place B.I.a.1.i - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Introduction of a new site of micronisation B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process | 10/08/2023 | n/a | of |
| IAIN/0043/G | This was an application for a group of variations. B.I.a.3.b - Change in batch size (including batch size ranges) of AS or intermediate - Downscaling down to 10-fold B.III.1.a.3 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - New certificate from a new manufacturer (replacement or addition)                                                                                                                                                                                                                                                                                                                 | 02/08/2023 | n/a |    |

<div style=\"page-break-after: always\"></div>

| II/0040/G   | This was an application for a group of variations.                                                                                                                                          | 20/07/2023   | n/a   |
|-------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|
| IA/0039     | B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer | 24/04/2023   | n/a   |
| IB/0037     | B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation                                                                        | 24/04/2023   | n/a   |
| IB/0036     | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                               | 15/12/2022   | n/a   |

<div style=\"page-break-after: always\"></div>

| WS/2334   | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Update of section 4.6 of the SmPC in order to update information on pregnancy and breast-feeding based on supporting published medical literature data on DolPHIN-1 (Dolutegravir in pregnant HIV mothers and their neonates, NCT02245022). The requested worksharing procedure proposed amendments to the Summary of Product Characteristics. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data   | 22/09/2022   | 15/03/2023   | SmPC        | Section 4.6. Pregnancy Dolutegravir crosses the placenta in humans. In pregnant women living with HIV, the median foetal umbilical cord concentration of dolutegravir was approximately 1.3-fold greater compared with the maternal peripheral plasma concentration. There is insufficient information on the effects of dolutegravir on neonates. Breast-feeding A median dolutegravir breast milk to maternal plasma ratio of 0.033 has been shown. For more information, please refer to the Summary of   |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| WS/2310   | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate                                                                                                                                                                                                                                                       | 01/09/2022   | n/a          |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| WS/2268   | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 01/09/2022   | 15/03/2023   | SmPC and PL | To update section 4.8 of the SmPC and section 4 of the PL to include the ADR 'weight increased' with a frequency 'common'.                                                                                                                                                                                                                                                                                                                                                                                   |

<div style=\"page-break-after: always\"></div>

|           | - Changes (Safety/Efficacy) of Human and Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                            |            |            |             | C.I.z Veterinary      |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-----------------------|
| IG/1537/G | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where | 09/08/2022 | n/a        |             | batch control/testing |
| IB/0032   | B.III.1.a.3 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - New certificate from a new manufacturer (replacement or addition)                                                                                                                                                                                                                                                                                                      | 14/06/2022 | n/a        |             |                       |
| II/0029   | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                                                                                                                                                                        | 10/06/2022 | 15/03/2023 | SmPC and PL |                       |
| IB/0030   | B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation                                                                                                                                                                                                                                                                                                                                                                                     | 02/05/2022 | n/a        |             |                       |
| WS/2210   | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.                                                                                                                                                                                                                                                                                                                                                            | 10/03/2022 | n/a        |             |                       |

<div style=\"page-break-after: always\"></div>

|         | Following the finalisation of procedure EMEA/H/C/WS1810 concerning submission of EuroSIDA (category 3 PASS) study, this Type II worksharing variation was proposed to address the removal of three important risks (Dolutegravir Hypersensitivity reactions, Hepatobiliary reactions and Serious rash) from all four dolutegravir- containing product EU-RMPs; Tivicay (dolutegravir), Triumeq (dolutegravir/abacavir/lamivudine), Dovato (dolutegravir/lamivudine) and Juluca (dolutegravir/rilpivirine) - i.e. deletion of safety concerns. In addition, the MAH took opportunity to propose a harmonisation of the risks across all four dolutegravir-containing product EU-RMPs and other minor updates (including study details and epidemiology data). The requested worksharing procedure proposed amendments to the Risk Management Plan (RMP). C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH   |            |            |             |
|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|
| WS/2192 | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 10/02/2022 | 15/03/2023 | SmPC and PL |

<div style=\"page-break-after: always\"></div>

| Update of section 4.8 of suicide' to the list of adverse with frequency 'rare' in dolutegravir/ abacavir/lamivudine dolutegravir/lamivudine finalisation of PSUSA procedure EMEA/H/C/PSUSA/00010075/202101 period 17 Jan 2020 to 16 of completed suicide from dolutegravir containing sponsored clinical trials. dolutegravir containing a worksharing procedure Dolutegravir/Rilpivirine accordance with Article of Commission Regulation Package Leaflet is updated identical wording. The proposed wording should with the suggested wording Dovato (footnote instead explanatory wording is acceptable already included footnote suicide attempt), Triumeq the wording in section 4 same as for the other three therefore adapted accordingly). Furthermore, it could be statement for patients in should consult their doctor neuropsychiatric side effects   |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|                     | (knowledge of the adverse effects) is possible. C.I.3.b - Change(s) in the SPC, Labelling or PL intended to implement the outcome of a procedure concerning PSUR or PASS or the outcome of the assessment done under A 45/46 - Change(s) with new additional data submitted by the MAH                                                               |            |            |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0027             | B.II.b.1.e - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch- release, batch control, primary and secondary packaging, for non-sterile medicinal products                                                                                                            | 21/12/2021 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| PSUSA/10075 /202101 | Periodic Safety Update EU Single assessment - dolutegravir, dolutegravir / abacavir / lamivudine, dolutegravir / lamivudine                                                                                                                                                                                                                          | 16/09/2021 | 15/11/2021 | SmPC and PL | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10075/202101.                                                                                                                                                                                                                                                                                                                     |
| IA/0025             | A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient                                                                                                         | 12/10/2021 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| WS/1990             | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Update of sections 4.2, 4.4 and 5.2 of the SmPC of the fixed-dose combination products Combivir, Dovato, Kivexa, Triumeq and Trizivir to include new information about use of the products in patients | 22/07/2021 | 20/08/2021 | SmPC and PL | Patients with a creatinine clearance between 30 and 49 mL/min receiving Combivir/Dovato/ Kivexa/ Triumeq/ Trizivir may experience a 1.6-to 3.3-fold higher lamivudine exposure (AUC) than patients with a creatinine clearance ≥50 mL/min. There are no safety d ata from randomized, controlled trials comparing Combivir/Dovato/ Kivexa/ Triumeq/ Trizivir to the individual components in patients with a creatinine clearance between 30 and 49 mL/min who |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| Furthermore, minor editorial changes have been implemented throughout the Product Information and the lists of local representatives have been updated for all products. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data   | with renal impairment.   |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------|

<div style=\"page-break-after: always\"></div>

|         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |            |            |             | Product Characteristics.                                                                       |
|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|------------------------------------------------------------------------------------------------|
| IB/0023 | B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 18/08/2021 | 15/11/2021 | SmPC        | To extend the shelf-life of the finished product as packaged for sale from 2 years to 3 years. |
| IG/1417 | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 03/08/2021 | n/a        |             |                                                                                                |
| II/0020 | Update of section 4.8 in order to add new safety information regarding hepatic safety and section 5.1 to include long-term efficacy and safety information, based on studies 204861 (GEMINI-1) and 205543 (GEMINI-2), listed as category 3 studies in the RMP. GEMINI-1 and GEMINI-2 were Phase III, randomised, double-blind, multicentre, parallel group, non-inferiority studies evaluating the efficacy, safety, and tolerability of dolutegravir plus lamivudine compared to dolutegravir plus tenofovir/emtricitabine in HIV-1-infected treatment- naïve adults. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 20/05/2021 | 20/08/2021 | SmPC and PL |                                                                                                |
| II/0019 | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 20/05/2021 | 20/08/2021 | SmPC        |                                                                                                |

<div style=\"page-break-after: always\"></div>

| IA/0022             | B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold increase compared to the originally approved batch size                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 07/04/2021   | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10075 /202001 | Periodic Safety Update EU Single assessment - dolutegravir, dolutegravir / abacavir / lamivudine, dolutegravir / lamivudine                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 17/09/2020   | 18/11/2020 | SmPC and PL | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10075/202001.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| II/0001             | Update of section 4.6 of the SmPC in order to update the safety information regarding the occurrence of neural tube defects with the dolutegravir -containing regimens based on the interim analysis from the Tsepamo study. This is a birth outcomes surveillance study being conducted in Botswana that was designed to evaluate adverse birth outcomes by HIV status and antiretroviral regimen, and to determine if there is an increased risk of neural tube defects among infants exposed to efavirenz at conception. This surveillance system captures all antiretroviral exposure including dolutegravir. The PL is updated accordingly. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 23/07/2020   | 18/11/2020 | SmPC        | Section 4.6 of the SmPC of Tivicay, Triumeq, Juluca and Dovato (dolutegravir-based products) has been updated to include safety information regarding the occurrence of neural tube defects (NTDs) with dolutegravir (DTG)- containing regimens based on interim analysis from a birth outcomes surveillance study being conducted in Botswana (the Tsepamo study). This is an observational cohort study focusing on the safety of antiretroviral therapy during pregnancy and was designed to evaluate adverse birth outcomes by HIV status and antiretroviral regimen. The assessment of the latest results (July 2020) from the study shows a small increase of neural tube defects; 7 cases in 3,591 deliveries (0.19%; 95% CI 0.09%, 0.40%) to mothers taking dolutegravir-containing regimens at the time of conception compared to 21 cases in 19,361 (0.11%: 95% CI 0.07%, 0.17%) women exposed to non- DTG regimens at the time of conception. The SmPC has been updated to include advice for women of childbearing potential to be counselled about the potential risk of NTD with DTG, including consideration of effective contraceptive measures. |

<div style=\"page-break-after: always\"></div>

|         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |            |            |                        | In addition, a recommendation to discuss the benefits and risks of continuing DTG versus switching to another antiretroviral regimen has been added in the case when a pregnancy is confirmed in the first trimester while on DTG.                                                                                                                                                                                                                                                                                                                                                    |
|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IG/1238 | A.1 - Administrative change - Change in the name and/or address of the MAH                                                                                                                                                                                                                                                                                                                                                                                                                                     | 17/06/2020 | 18/11/2020 | SmPC, Labelling and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| IA/0016 | B.II.b.4.a - Change in the batch size (including batch size ranges) of the finished product - Up to 10-fold compared to the originally approved batch size                                                                                                                                                                                                                                                                                                                                                     | 15/06/2020 | n/a        |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| IA/0015 | B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place                                                                                                                                                                                                                                                                                                                                     | 15/06/2020 | n/a        |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| IB/0014 | B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation                                                                                                                                                                                                                                                                                                                                                                                           | 30/04/2020 | n/a        |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| WS/1762 | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Update of sections 4.3 and 4.5 of the SmPC in order to add a new contraindication in relation to the co- administration of dolutegravir with medicinal products with narrow therapeutic windows that are substrates of organic cation transporter 2 (OCT2), including but not limited to fampridine (also known as dalfampridine).The Package Leaflet is updated | 06/02/2020 | 01/04/2020 | SmPC and PL            | A new contraindication is added to the Product information for dolutegravir containing products namely dolutegravir (DTG; TIVICAY), dolutegravir/abacavir/lamivudine (DTG/ABC/3TC; TRIUMEQ), dolutegravir/rilpivirine fixed dose combination (DTG/RPV FDC; JULUCA), and dolutegravir/lamivudine (DTG/3TC; DOVATO), to warn of concurrent administration of dolutegravir with medicinal products with narrow therapeutic windows, that are substrates of OCT-2, including but not limited to fampridine (also known as dalfampridine). Fampridine is a substrate of OCT2 with a narrow |

<div style=\"page-break-after: always\"></div>

|           | accordingly. In addition, the products information have been updated to reflect the following changes: - remove the drug-drug interactions for products no longer authorised in the EU (boceprevir, dofetilide, nelfinavir) - remove the inverted triangle for additional monitoring for Dovato only. Editorial changes have been made to the product information. In addition, the Marketing authorisation holder (MAH) took the opportunity to update the list of local representatives in the Package Leaflets. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                   |            |     | therapeutic index and could show an increased risk of seizures at elevated concentrations. While the proposed interaction has not been formally investigated in a drug interaction study for dolutegravir, the contradiction is accepted given the information stated in the approved product labelling for fampridine, and the understanding of dolutegravir potential to inhibit OCT2. The SmPC section 4.3 and 4.5 and the PL have been updated accordingly.   |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| WS/1738/G | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient B.I.a.1.a - Change in the manufacturer of AS or of a | 20/02/2020 | n/a |                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| starting material/reagent/intermediate proposed manufacturer pharmaceutical group as manufacturer B.I.a.1.f - Change in the starting material/reagent/intermediate Changes to quality control the AS -replacement or batch control/testing takes B.I.a.1.f - Change in the starting material/reagent/intermediate Changes to quality control the AS -replacement or batch control/testing takes B.I.a.1.f - Change in the starting material/reagent/intermediate Changes to quality control the AS -replacement or batch control/testing takes B.I.a.1.i - Change in the starting material/reagent/intermediate Introduction of a new site B.I.a.2.a - Changes in the AS - Minor change of the AS B.I.a.3.a - Change in batch ranges) of AS or intermediate increase compared to the size B.I.a.3.a - Change in batch ranges) of AS or intermediate   |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|                     | size B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold increase compared to the originally approved batch size                                                                                                                                                                                                                                                                                                                                                                                                                     |            |            |      |                                   |
|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------|-----------------------------------|
| II/0009             | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 13/02/2020 | 18/11/2020 | SmPC |                                   |
| II/0008             | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 13/02/2020 | 18/11/2020 | SmPC |                                   |
| PSUSA/10075 /201907 | Periodic Safety Update EU Single assessment - dolutegravir, dolutegravir / abacavir / lamivudine, dolutegravir / lamivudine                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 13/02/2020 | n/a        |      | PRAC Recommendation - maintenance |
| IB/0012/G           | This was an application for a group of variations. B.I.a.1.a - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The proposed manufacturer is part of the same pharmaceutical group as the currently approved manufacturer B.I.a.1.a - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The proposed manufacturer is part of the same pharmaceutical group as the currently approved manufacturer B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold | 10/01/2020 | n/a        |      |                                   |

<div style=\"page-break-after: always\"></div>

|           | to the originally approved batch size B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold increase compared to the originally approved batch size B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate   |            |     | increase compared   |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|---------------------|
| IB/0010   | B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other                                                                                                                                                                                                                                                                                                        | 04/12/2019 | n/a | variation           |
| IAIN/0006 | B.I.a.1.a - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The proposed manufacturer is part of the same pharmaceutical group as the currently approved manufacturer                                                                                                                                                                                                    | 22/11/2019 | n/a |                     |
| IB/0003   | B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation                                                                                                                                                                                                                                                                                              | 29/10/2019 | n/a |                     |
| IB/0004   | B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter)                                                                                                                                                                                               | 18/10/2019 | n/a |                     |

<div style=\"page-break-after: always\"></div>

| IA/0002/G   | This was an application for a group of variations.   | 13/09/2019   | n/a   |
|-------------|------------------------------------------------------|--------------|-------|